https://assets.capyfin.com/instruments/678fdc13234e27009c5d5b78.png avatar
Teleflex
🇺🇸 NYSE:TFX
View Company
OverviewEarningsDividends
•
Dec 31, 2021

Teleflex Q4 2021 Earnings Report

Teleflex reported solid fourth quarter and full year results driven by strong execution and a diversified product portfolio.

Key Takeaways

Teleflex Incorporated announced its Q4 2021 financial results, with reported revenues of $761.9 million, a 7.1% year-over-year increase, and adjusted diluted EPS of $3.60, up 10.8% year-over-year. The company provided 2022 guidance, including GAAP revenue growth expected to be 2.3% to 3.8% and adjusted diluted EPS from continuing operations of $13.70 to $14.30.

Reported revenues increased by 7.1% year-over-year to $761.9 million.

Constant currency revenue growth was 7.9%.

GAAP diluted EPS from continuing operations was $2.69, compared to $1.62 in the prior year period.

Adjusted diluted EPS from continuing operations increased by 10.8% year-over-year to $3.60.

Total Revenue
$762M
Previous year: $711M
+7.1%
EPS
$3.6
Previous year: $3.25
+10.8%
Gross Profit
$420M
Previous year: $384M
+9.4%
Cash and Equivalents
$445M
Previous year: $376M
+18.4%
Total Assets
$6.87B
Previous year: $7.15B
-3.9%

Teleflex

Teleflex

Teleflex Revenue by Segment

Teleflex Revenue by Geographic Location

Forward Guidance

Teleflex provided its outlook for full year 2022, expecting GAAP revenue growth of 2.3% to 3.8% and adjusted diluted earnings per share of $13.70 to $14.30.

Positive Outlook

  • GAAP revenue growth expected to be 2.3% to 3.8%.
  • Constant currency revenue growth of 4.0% to 5.5% inclusive of a 1.6% headwind from the initial phase of the respiratory divestiture completed on June 28, 2021.
  • GAAP diluted EPS from continuing operations of $8.90 to $9.50.
  • Adjusted diluted EPS from continuing operations guidance range of $13.70 to $14.30 inclusive of an estimated $0.17 headwind from the respiratory divestiture.
  • The company believes Teleflex remains well-positioned to drive durable growth and manage the challenges of the current environment.

Challenges Ahead

  • GAAP revenue growth reflects an estimate of an approximately 1.7% negative impact of foreign exchange rate fluctuations.
  • Constant currency revenue growth includes an approximately 1.6% year-over-year headwind from the initial phase of the respiratory divestiture completed on June 28, 2021.
  • The divestiture of the respiratory assets is estimated to be dilutive to 2022 adjusted earnings per share by $0.17.
  • Adverse economic conditions associated with the COVID-19 global health pandemic.
  • Potential changes in business relationships with major customers or suppliers.

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View Teleflex